The FDA Peptide Advisory Vote: What Actually Happened

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on whether seven peptides should be added to the section 503A bulk drug substances list. Six got a favorable vote. One did not. Within hours the internet had compressed that into "the FDA approved peptides," which is wrong on three separate counts — wrong about who voted, wrong about what they voted on, and wrong about what a vote does.

The honest version is more interesting than the hype, so here it is up front. An advisory committee — not the FDA — recommended six substances, by narrow margins, over the written objection of the FDA's own scientific reviewers. Every substance was evaluated for one specific medical indication, and not one of those indications is athletic recovery, tendon healing, injury repair, or performance. And a favorable advisory vote does not put anything on any list; only a final rule does, and the last time the FDA completed that rulemaking it took roughly three years.

Nothing about what is legal to buy, prescribe, or compound in the United States changed on July 24, 2026.

What PCAC is, and what it isn't

The Pharmacy Compounding Advisory Committee advises the FDA on which bulk drug substances compounding pharmacies may legally use under section 503A of the Federal Food, Drug, and Cosmetic Act. That is a narrow question. It is not "does this drug work," and it is emphatically not "should this drug be approved." Drug approval runs through an entirely different process — a new drug application, controlled human trials, an approved label.

The FDA states the committee's status plainly on the meeting page itself: advisory committees "make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so"¹. That sentence is the whole story of the July meeting in miniature. The panel gave advice. The agency now decides what to do with it.

The 503A list itself is codified at 21 CFR 216.23. It is worth knowing how small it is. As of today the entire list — every bulk substance a compounding pharmacy may use under this provision — is six entries: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide. Five of those six carry an explicit route restriction: "for topical use only"². There is no peptide on the 503A list. There never has been. That route-restriction precedent matters for what comes next, because it shows the FDA is willing to list a substance for a narrow use and only that use.

The seven substances — and the seven indications

This is the part almost every write-up skipped, and it is the single most useful fact on this page. The FDA published, in advance, the exact use it evaluated for each substance. From the agency's own meeting notice¹:

• •BPC-157 (free base and acetate) — reviewed for ulcerative colitis.
• •KPV (free base and acetate) — reviewed for wound healing and inflammatory conditions.
• •TB-500 (free base and acetate) — reviewed for wound healing.
• •MOTS-c (free base and acetate) — reviewed for obesity and osteoporosis.
• •Emideltide, also called delta sleep-inducing peptide or DSIP — reviewed for opioid withdrawal, chronic insomnia, and narcolepsy.
• •Semax — reviewed for cerebral ischemia, migraine, and trigeminal neuralgia.
• •Epitalon — reviewed for insomnia.

Read that list again against what these peptides are actually sold for. BPC-157 is marketed to athletes for tendons; the FDA reviewed it for an inflammatory bowel disease. TB-500 is marketed for injury repair; the FDA reviewed it for wound healing. MOTS-c is marketed for endurance and mitochondrial performance; the FDA reviewed it for obesity and osteoporosis. Semax is sold as a nootropic; the FDA reviewed it for stroke-related brain injury and facial nerve pain.

No substance at this meeting was evaluated for athletic recovery, injury repair, tendon or ligament healing, muscle growth, or performance. Anyone telling you the FDA "looked at BPC-157 for tendons and said yes" is describing a meeting that did not happen. The evidence picture for the uses athletes actually care about is unchanged, and we cover it substance by substance in our reviews of BPC-157 for healing and recovery, TB-500 for recovery, and MOTS-c for endurance.

There is a real nuance here, and it cuts both ways. If a substance eventually lands on the 503A list, a clinician writing a prescription is not legally confined to the indication the FDA reviewed — prescribing outside a reviewed use is ordinary clinical discretion⁶. So a listed BPC-157 could, in practice, end up prescribed for a tendon. What that would not mean is that the FDA assessed the tendon evidence and found it adequate. It didn't. It assessed ulcerative colitis.

The votes — and who cast them

Now the tallies. The FDA has not published meeting minutes, so every number below comes from trade and news coverage of the room, not from an FDA document. We attribute accordingly.

Day one produced four favorable votes. Both the free-base and acetate forms of each substance were voted separately and reached the same result each time: BPC-157, KPV, and TB-500 each cleared 8–6 with one abstention; MOTS-c cleared 7–5 with two abstentions³⁴. Day two produced two more: Semax 8–5 in favor, and Epitalon 7–5 in favor with one abstention. Emideltide (DSIP) was voted down, 6–7, with one abstention — the only substance of the seven to fail⁵.

One honest caveat on Epitalon: outlets differ slightly on that tally, with at least one reporting 7–4. Until the FDA posts minutes, treat the exact count as approximate and the direction — narrowly favorable — as the reliable part.

Then there is the composition of the committee, which is the fact that actually explains the outcome. Ahead of the meeting the FDA added eight new members to the panel; most had ties to the peptide industry, including physicians running clinics and companies that sell peptide protocols⁶⁷.

NBC News counted the votes by member, and the arithmetic is stark: for BPC-157, KPV, and TB-500, all eight of the new appointees voted yes — six members voted no and one abstained. For MOTS-c, seven of the new appointees voted yes, five voted no, and two abstained⁷.

In other words, on day one the favorable side of every vote was composed entirely of members appointed weeks earlier. Remove those appointments and the "yes" column is empty. That is not a conspiracy theory; it is a headcount published by a news organization that sat through the meeting. It is also the reason "an FDA panel endorsed peptides" is a misleading summary of what the room did.

FDA's own scientists recommended against all seven

The other fact the marketing coverage omits: the agency's reviewers opposed the entire slate. FDA scientists spent the meeting laying out the absence of reliable human data for all seven substances and advised the panel to vote no⁶⁴.

Their objection was not only "the trials don't exist," though largely they don't. It was more basic. FDA official Russell Wesdyk told the committee that the foundational problem was defining the substances at all, because material sold under the same peptide name varies considerably in composition: "We can't create quality standards until we actually know what it is"⁶. Reviewers also raised immunogenicity risk and peptide-related impurities, and for Epitalon specifically noted there was no published efficacy data for insomnia at all⁵.

That is an unusual posture for an advisory meeting. Committees routinely disagree with agency staff at the margins. A clean sweep against the reviewers' recommendation, carried by a bloc of newly seated members, is a different animal — and it is the reason the FDA's eventual decision here is genuinely hard to predict rather than a formality.

What still has to happen — the actual pathway

A favorable PCAC vote is roughly the midpoint of a long administrative process, not the end of one. The full sequence is:

1. 1.A substance is nominated by the public for the 503A list.
2. 2.The FDA performs a four-factor review. Those factors are written into the regulation: the substance's physical and chemical characterization; safety issues raised by its use in compounded products; available evidence of effectiveness or lack of effectiveness; and historical use in compounding, including the conditions treated and references in peer-reviewed literature².
3. 3.PCAC advises. This is the step that happened in July.
4. 4.The FDA issues a proposed rule and opens a public comment period.
5. 5.The FDA issues a final rule.

Only step five puts a substance on the list. Everything before it is process. The FDA has said it will act, if it acts, through notice-and-comment rulemaking rather than an announcement at the meeting³.

The precedent: about three years, start to finish

How long does step four to step five take? There is exactly one completed precedent for the 503A bulks list, and it is worth walking through because it is the only real-world data point anyone has.

PCAC took up the first tranche of nominated substances across 2015 and 2016. The FDA published its proposed rule on December 16, 2016, with comments closing March 16, 2017⁸. The final rule published February 19, 2019 and took effect March 21, 2019⁹. That rule placed six substances on the list and declined four others⁹ — the same six-substance list codified at 21 CFR 216.23 today².

From advisory meeting to effective rule: roughly three years. NPR's reporting on the July 2026 meeting frames the timeline the same way, noting the rulemaking "could stretch into next year or 2028"⁶.

⚠ You will see a specific "proposed rule within 9 to 18 months" figure circulating widely right now. It appears on vendor and affiliate blogs, not in any FDA document. The FDA has not published a timeline for this rulemaking. Vendors are repeating that number; the agency has said nothing. Treat it as marketing until the agency says otherwise.

What is legal today: nothing changed

This is the practical section, and it is short.

No peptide from this meeting is on the 503A list. The list is still the same six substances it has been since 2019². A compounding pharmacy that could not legally use BPC-157 on July 22 still cannot use it today. Nothing about the July votes altered a compounder's legal position, and nothing altered the status of the "research use only" vials sold online — which are unapproved drugs regardless of what any committee recommends, a point we unpack in where to buy peptides and research-chemical legality and peptide vendor red flags. For the whole legal picture, see are peptides legal?.

The pre-meeting status of these substances is also routinely misreported. BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon are not currently in the FDA's live Category 2 table of substances that may present significant safety risks. They sit in that page's second table — substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators" — alongside AOD-9604, CJC-1295, LL-37, GHK-Cu, Dihexa, Melanotan II, PEG-MGF, Selank, and thymosin alpha-1¹⁰. The live Category 2 table still holds the growth-hormone secretagogues athletes ask about most — GHRP-2, GHRP-6, ipamorelin acetate, kisspeptin-10, and ibutamoren mesylate¹⁰. Several sites get this backwards. "Withdrawn by the nominator" is not a safety clearance; it means the nomination was pulled.

The misbranding rule that survives the rulemaking

Here is the provision that makes "FDA approved" language a legal problem rather than merely an inaccurate one — and it applies after a substance wins its rulemaking, not just before.

21 CFR 216.23(d) states that there are inadequate data to demonstrate the safety or efficacy of any drug compounded with a listed substance, and then this, verbatim: any person who represents that a compounded drug made with a bulk drug substance that appears on this list "is FDA approved, or otherwise endorsed by FDA generally or for a particular indication, will cause the drug to be misbranded" under sections 502(a) and/or 502(bb) of the Federal Food, Drug, and Cosmetic Act².

Read that carefully. Even for a substance that has already made it onto the list, calling the compounded product FDA-approved or FDA-endorsed misbrands it. The regulation anticipated exactly the marketing wave now underway, and pre-emptively made it a misbranding issue. There is no version of the 503A pathway that ends with "FDA-approved BPC-157."

What this means for a tested athlete: nothing

For anyone competing under the World Anti-Doping Agency code, the July vote is not merely insufficient — it is irrelevant. WADA classification and US compounding policy are separate instruments in separate jurisdictions. BPC-157 is prohibited at all times under S0, non-approved substances, and the US Anti-Doping Agency says so directly¹¹. The Department of Defense's supplement-safety program states flatly that BPC-157 is an unapproved drug that cannot be legally prescribed or sold over the counter, and is not a dietary ingredient¹².

An advisory recommendation on a compounding list does not create a marketing authorization, which is what S0 turns on. If anything, a future listing would arguably strengthen the S0 case for substances still lacking approval anywhere. We walk through the anti-doping mechanics in the WADA 2026 prohibited list for peptides and the detection side in do peptides show up on drug tests?.

What's next: February 2027

The committee is scheduled to meet again before the end of February 2027⁶. Regulatory trade press reports the next slate as cathelicidin LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and pegylated mechano growth factor (PEG-MGF)¹³ — five more substances currently sitting in the withdrawn-nominations table¹⁰. The FDA's own advisory calendar has not yet named the substances for that meeting, so treat the list as trade-press reporting rather than agency confirmation.

If you want the science on two of those before the arguments start, we have already reviewed GHK-Cu for recovery and PEG-MGF.

The bottom line

Six peptides received a favorable, non-binding recommendation from an advisory committee whose favorable votes on day one came entirely from eight members appointed shortly before the meeting, against the written recommendation of the FDA's own scientific reviewers⁷⁶. Each was evaluated for one narrow medical indication — ulcerative colitis, wound healing, obesity and osteoporosis, cerebral ischemia, insomnia — and none for athletic recovery, tendon repair, or performance¹. Nothing is on the 503A list; the list remains the six substances codified in 2019². A proposed rule, a comment period, and a final rule all still have to happen, and the only completed precedent took about three years⁸⁹.

The substance-by-substance breakdowns are here: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. For how these peptides rank on actual evidence rather than regulatory news, start with our best recovery peptides hub and the pillar on peptides for recovery and healing. And for the myths this news cycle produced, see the 2026 FDA peptide reclassification.